Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (1023)	2/6/1998 9:47:00 AM
From: WeirdPro Randy	Read Replies (1) \| Respond to of 1359

<< Certainly there are hundreds, if not thousands, of attorneys and their investigators searching for dirt regarding IPIC and Redux and not a SINGLE story in 2 months! No new reports of death's or heart problems.>> Actually Kurt, there is really no good evidence to implicate Redux at all, other than its "guilt by association" with phen-fen". As has been pointed out, the original FDA survey unveils a 13% incidence of valvular disease in Redux patients.....when one looks closer, this 13% comes from 2 out of 15 patients out of a survey containing 291 patients! Unless the studies to come creates some evidence of correlation, now that no one has been taking Redux for 5 months, how is anyone going to make a case (other than from the easily degradable Khan study) that Redux is bad? Even the idea of settlement is maddening, let the case continue and the settlements revolve around phen-fen alone........that's where the real money lies anyway (in terms of patient populations and deep pockets).